Labor Day heralds the end of summer and the return of children to school, where food allergies are prevalent. To combat allergic reactions, EpiPens have been a staple in schools, but this academic year will see the introduction of the first nasal spray epinephrine, neffy. Approved by the FDA, neffy offers an alternative to injectable epinephrine for type 1 allergic reactions. Marketed by ARS Pharma, neffy’s approval came earlier than expected, providing a positive outlook for the upcoming school season. Additionally, recent regulatory news includes expanded approvals for smallpox vaccines, Covid-19 vaccines, cancer drugs, and other treatments.
Source link
Highly Anticipated FDA Decision Comes Just in Time for Back-to-School Season
